We are live on
!
Find out more
ACA
Acorn Capital Advisors Portfolio holdings
AUM
$366M
1-Year Est. Return
474.6%
This Fund
S&P 500
This Quarter
Est. Return
+116.39%
1 Year Est. Return
+474.6%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$295M
AUM Growth
+$98.1M
(+50%)
Cap. Flow
+$12.4M
Cap. Flow
% of AUM
4.21%
Top 10 Holdings %
Top 10 Hldgs %
88.72%
Holding
21
New
1
Increased
4
Reduced
3
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verastem
VSTM
|
+$6.15M |
| 2 |
HELP
Cybin Inc
HELP
|
+$5.4M |
| 3 |
UroGen Pharma
URGN
|
+$4.09M |
| 4 |
LONA
LeonaBio Inc
LONA
|
+$2.3M |
| 5 |
Jasper Therapeutics
JSPR
|
+$811K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TERN
Terns Pharmaceuticals
TERN
|
+$5.2M |
| 2 |
Q32 Bio
QTTB
|
+$876K |
| 3 |
YARW
Yarrow Bioscience
YARW
|
+$235K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TERN
1
DELISTED
Terns Pharmaceuticals
TERN
| $70.5M | 23.9% |
1,746,264
-225,000
| -11% | -$5.2M |
|
2
CG Oncology
CGON
$6.71B
| $47M | 15.92% |
1,131,501
| – | – |
|
|
3
UroGen Pharma
URGN
$2.2B
| $33.9M | 11.49% |
1,448,420
+188,671
| +15% | +$4.09M |
|
4
Trevi Therapeutics
TRVI
$2.21B
| $26.9M | 9.1% |
2,144,844
| – | – |
|
5
Puma Biotechnology
PBYI
$490M
| $24.6M | 8.33% |
4,131,299
| – | – |
|
6
Candel Therapeutics
CADL
$869M
| $14.6M | 4.94% |
2,580,517
| – | – |
|
|
HELP
7
Cybin Inc
HELP
$1.01B
| $12.9M | 4.36% |
1,573,023
+838,629
| +114% | +$5.4M |
|
|
8
Verastem
VSTM
$710M
| $11.3M | 3.84% |
1,469,153
+689,655
| +88% | +$6.15M |
|
|
BCAX
9
Bicara Therapeutics
BCAX
$1.51B
| $10.8M | 3.67% |
643,382
| – | – |
|
10
Protara Therapeutics
TARA
$219M
| $9.34M | 3.16% |
1,752,115
| – | – |
|
|
OKUR
11
OnKure Therapeutics
OKUR
$121M
| $8.24M | 2.79% |
2,839,674
| – | – |
|
12
Cardiff Oncology
CRDF
$101M
| $5.51M | 1.87% |
1,962,084
| – | – |
|
|
LONA
13
LeonaBio Inc
LONA
$64.9M
| $3.8M | 1.29% |
+501,739
| New | +$2.3M |
|
|
14
Jasper Therapeutics
JSPR
$21.3M
| $3.27M | 1.11% |
1,786,492
+403,852
| +29% | +$811K |
|
15
Aura Biosciences
AURA
$699M
| $3.25M | 1.1% |
595,744
| – | – |
|
|
WHWK
16
Whitehawk Therapeutics
WHWK
$237M
| $2.76M | 0.93% |
1,139,363
| – | – |
|
|
BCAB
17
DELISTED
BIOATLA INC
BCAB
| $2.76M | 0.93% |
96,702
| – | – |
|
|
18
Q32 Bio
QTTB
$331M
| $1.64M | 0.56% |
493,425
-310,000
| -39% | -$876K |
|
19
X4 Pharmaceuticals
XFOR
$347M
| $1.09M | 0.37% |
273,349
| – | – |
|
20
Acrivon Therapeutics
ACRV
$74.6M
| $977K | 0.33% |
405,237
| – | – |
|
|
YARW
21
Yarrow Bioscience
YARW
$76.1M
| $827 | ﹤0.01% |
29
-11,702
| -100% | -$235K |
|
Similar funds
WA
ICP
CIC
SA
PLC
FIBOI
SCP
VST
Acorn Capital Advisors's Q4 2025 Portfolio in Review
As of Q4 2025, Acorn Capital Advisors held 21 positions worth $295M, up 50% from $197M the previous quarter. Its ten largest holdings account for 89% of the portfolio.
Acorn Capital Advisors deployed $12.4M of net new capital in Q4 2025, opening 1 new position and adding to 4 existing holdings. Its largest new stake was LeonaBio Inc: 501,739 shares worth $3.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $5.2M trimmed.
- Acorn Capital Advisors's largest Q4 2025 buy was LeonaBio Inc: 501,739 shares worth $3.8M.
- Acorn Capital Advisors added most to Verastem in Q4 2025, an estimated $6.15M increase.
- Acorn Capital Advisors's biggest Q4 2025 reduction was Terns Pharmaceuticals, cutting an estimated $5.2M.
- Acorn Capital Advisors's ten largest holdings make up 89% of its $295M portfolio in Q4 2025.
- Acorn Capital Advisors opened 1 new position and closed 0 in Q4 2025.
- Acorn Capital Advisors's portfolio value rose 50% quarter-over-quarter to $295M.
Based on Acorn Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.